Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma

NCT00700336 is registered in ClinicalTrials.gov with CanBas Co. Ltd. as lead sponsor.

NCT NCT00700336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00700336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma
Lead sponsor
CanBas Co. Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
May 31, 2008
Completion date
November 30, 2012
Enrollment
69 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

malignant pleural mesothelioma, solid tumors